Ace Therapeutics, a specialized contract research organization (CRO) focused on translational blood disorder research, has announced a comprehensive suite of integrated preclinical hematology CRO services designed to accelerate the discovery and regulatory advancement of novel therapeutics for a broad spectrum of hematologic diseases. The services aim to address bottlenecks in model translatability and study execution that biotech and pharmaceutical developers face when advancing gene therapies, biologics, small molecules, RNA modalities, and cell-based treatments for blood disorders.
Hematologic diseases encompass complex pathologies affecting red blood cells, white blood cells, platelets, bone marrow, and lymphatic systems, including inherited anemias, autoimmune blood conditions, coagulation defects, myelodysplastic syndromes, and hematopoietic failure disorders. Ace Therapeutics addresses these challenges through vertically integrated services that unify in vitro modeling, in vivo efficacy testing, biomarker profiling, PK/PD analysis, safety toxicology, and custom biospecimen analytics under a fully integrated scientific framework.
The company offers a robust collection of in vivo hematologic disease models built across multiple preclinical species, including mice, rats, dogs, and non-human primates. The model bank encompasses genetically engineered lines, chemically induced disease platforms, antibody-triggered autoimmune systems, and patient-derived xenograft constructs. For genetic hematological disorders, Ace Therapeutics maintains transgenic and knockout mouse models for sickle cell disease, α- and β-thalassemia, G6PD deficiency, and hereditary spherocytosis. Researchers investigating bone marrow failure can access radiation or cyclophosphamide-induced myelosuppression rodents, immune-mediated aplastic anemia lymphocyte transfer models, and FANCA-knockout Fanconi anemia lines.
In addition to in vivo models, Ace Therapeutics' preclinical hematology CRO services deliver cutting-edge in vitro modeling platforms, including biomimetic 3D hematopoietic culture systems that reconstruct bone marrow niche microenvironments, patient-specific iPSC-derived hematopoietic disease lines, and functional assays using primary human CD34+ hematopoietic stem and progenitor cells sourced from bone marrow, cord blood, and mobilized peripheral blood.
Beyond model development, the services extend across the full drug development lifecycle, from target identification and CRISPR-based validation to specialized PK/PD profiling tailored to blood disorder therapeutics. Hematology-focused safety pharmacology and toxicology assessments evaluate candidate treatments for impacts on hematopoiesis, clotting function, endothelial integrity, and organ toxicity in blood-rich tissues such as the spleen and bone marrow. Specialized technical support is offered for all therapeutic modalities, including small-molecule iron chelators, JAK inhibitors, monoclonal antibodies, LNPs delivering RNA therapeutics, AAV/lentiviral gene vectors, and engineered cell therapies for inherited hemoglobinopathies and bleeding disorders.
All research workflows adhere to standardized operating procedures with rigorous quality control to guarantee reproducible, regulatory-ready data. Clients seeking customized research programs can collaborate with Ace Therapeutics to design tailored study projects, including custom CRISPR-edited animal lines, humanized hematopoietic models, and niche-focused in vitro co-culture systems for rare hematological conditions.
